This study involves people with heart failure (HF) and a weak heart pumping function, known as reduced left ventricular ejection fraction (LVEF) of less than 40%. Participants must have had heart failure for at least 3 months. The study tests two medicines: vicadrostat and empagliflozin, to see if they help these heart patients. Participants are randomly placed in one of two groups. One group takes the study medicines, while the other takes a placebo, which looks like the real medicine but has no active ingredient. The duration of taking these tablets could range from 1 to 3.5 years. Participants can continue their regular heart failure treatments during the study.

• Participation may last up to 3.5 years with regular site visits and phone check-ins.
• Participants need to answer questions about their health regularly.
• Doctors will track any worsening symptoms or hospital visits due to heart failure.